Esperion Therapeutics (ESPR) Cash from Investing Activities (2012 - 2026)

Esperion Therapeutics has reported Cash from Investing Activities for 14 years, with the latest figure at -$189000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities changed N/A year-over-year to -$189000.0; the trailing twelve-month figure through Mar 2026 stood at -$189000.0 (up 22.54% YoY), and the FY2024 full-year result was -$317000.0, down 100.75% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$189000.0, down from -$167000.0 in the prior quarter.
• The five-year high for Cash from Investing Activities was $33.0 million in Q3 2022, with the low at -$18.1 million in Q1 2022.
• Historically, Cash from Investing Activities has averaged $5.0 million across 4 years, with a median of -$75000.0 in 2024.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities jumped 250.0% — and 2024, when it tumbled 100.44%.
• Esperion Therapeutics' Cash from Investing Activities stood at -$11.8 million in 2022, then soared by 248.38% to $17.5 million in 2023, then sank by 100.95% to -$167000.0 in 2024, then retreated by 13.17% to -$189000.0 in 2026.
• The last three Cash from Investing Activities figures came in at -$189000.0 (Q1 2026), -$167000.0 (Q3 2024), and -$77000.0 (Q2 2024), per Business Quant data.